PC
ASBP

Periscope Capital’s Aspire Biopharma ASBP Stock Holding History

Periscope Capital’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42
Closed -$6.59K – 454
2025
Q4 		$6.59K Hold
42
– – ﹤0.01% 336
2025
Q3 		$10.3K Sell
42
-21
-33% -$10.5K ﹤0.01% 271
2025
Q2 		$15K Hold
63
– – ﹤0.01% 206
2025
Q1 		$33.8K Buy
+63
New +$436K 0.01% 136
2024
Q2 		– Sell
-146
Closed -$1.93M – 362
2024
Q1 		$1.93M Hold
146
– – 0.49% 65
2023
Q4 		$1.91M Sell
146
-22
-13% -$289K 0.32% 106
2023
Q3 		$2.18M Buy
168
+42
+33% +$541K 0.25% 146
2023
Q2 		$1.6M Sell
126
-984
-89% -$12.4M 0.12% 236
2023
Q1 		$14M Buy
1,110
+245
+28% +$3.06M 0.65% 28
2022
Q4 		$10.7M Buy
865
+61
+8% +$747K 0.46% 41
2022
Q3 		$9.78M Buy
804
+190
+31% +$2.29M 0.28% 97
2022
Q2 		$7.36M Buy
+614
New +$7.35M 0.2% 195

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.17B AUM 29.21% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Periscope Capital's ASBP Position: Q1 2026 in Review

Periscope Capital sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 42 shares — an estimated $6.59K sold.

Periscope Capital first reported a position in ASBP in Q2 2022 and held it in 12 quarters. The position peaked at $14M in Q1 2023. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

  • Periscope Capital reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
  • Periscope Capital sold 42 Aspire Biopharma shares in Q1 2026, an estimated $6.59K.
  • Periscope Capital first reported a position in Aspire Biopharma in Q2 2022 and held it in 12 quarters.
  • Periscope Capital's Aspire Biopharma position peaked at $14M in Q1 2023.
  • 12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Periscope Capital's 13F filing for Q1 2026, filed 14 May 2026.